한글목차

파킨슨병(PD)은 임상적으로 진전, 응축, 서맥과 같은 현저한 운동 증상을 동반하는 운동 장애로 분류되는 신경퇴행성 난치병입니다. PD의 임상 증상은 자세 불안정, 휴식시 진전, 보행장애를 특징으로 하며, 이는 흑질의 A9 도파민작용성 뉴런의 진행성 상실에 기인하며, 서맥, 안정시진전, 경직, 자세 장애와 관련된 운동 증상과 저혈압, 급속 안구 운동, 수면 행동 장애, 우울증과 같은 비 운동 증상이 동반됩니다. PD는 알츠하이머병에 이어 고령자에게 많은 만성 진행성 신경퇴행성 질환으로 세계 65세 이상의 환자의 1-2%가 병을 앓고 있습니다. 현재 PD의 비유전적 사례를 진단하기 위한 혈액 검사나 임상 검사는 없습니다. 진단은 주로 환자의 병력과 신경학적 진찰에 기초하여 이루어집니다. PD의 진단을 뒷받침하는 또 다른 특징은 약수처리 시작 후 환자의 개선입니다. 현재의 치료는 증상의 완화를 초래하지만, 질병의 진행을 멈추거나 지연시키는 치료법은 아직 없습니다. PD의 치료법은 아직 확립되지 않았지만, 약물요법, 수술적 개입, 물리치료 및 작업요법과 같은 기존의 치료법은 주요 증상을 관리하고 삶의 질을 최대한 길게 유지하는 데 도움이 됩니다.

2023년에는 주요 7개국 전체에서 18세 이상 남녀의 PD 유병자 수는 263만 6,930명으로 진단되었습니다. 미국은 97만 4,348명으로 가장 많고, 스페인은 13만 1,264명으로 가장 적습니다. 주요 7개국 전체에서 PD와 진단받은 유병자 수는 2033년까지 314만 7,624례로 증가하고 예측기간 중 연간 성장률(AGR)은 1.94%로 예측됩니다.

본 보고서에서는 주요 7개국 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)에서 파킨슨병의 위험인자, 병존질환, 세계 및 과거의 역학 동향에 대해 개략하여 파킨슨병의 진단된 발병 사례 라고 진단된 유병률에 관한 10년간의 역학 예측 등을 정리했습니다.

목차

제1장 파킨슨병: 주요 요약

제2장 역학

• 병의 배경
• 위험요인과 합병증
• 세계와 역사의 동향
• 주요 7개국 예측 조사 방법
• PD의 역학적 예측(2023-2033년)
  • 진단이 끝난 PD의 유병률
  • 진단이 끝난 PD의 유병률, 연령별
  • 진단이 끝난 PD의 유병률, 성별
  • 진단이 끝난 PD의 유병률, HY 임상 병기 분류별
  • 진단이 끝난 PD의 유병률, 유전형별
  • 진단이 끝난 PD의 유병률, 운동 합병증별
  • 진단이 끝난 PD의 유병률, 신경정신의학적 합병증별
• 토론

제3장 부록

영문목차

Parkinson's disease (PD) is an incurable neurodegenerative disease clinically categorized as a movement disorder with prominent motor symptoms, including tremors, rigidity, and bradykinesia (Hoehn and Yahr, 1967; Poewe et al., 2017). The clinical presentation of PD is characterized by postural instability, resting tremors, and gait problems that result from the progressive loss of A9 dopaminergic neurons in the substantia nigra pars compacta (Delic et al., 2020). PD is associated with motor symptoms involving bradykinesia, resting tremor, rigidity, and postural disturbances, as well as non-motor symptoms, including hyposmia, rapid eye movements, sleep behavior disorder, and depression (World Health Organization, 2023). PD is the second most common chronic progressive neurodegenerative disorder in the elderly, following Alzheimer's disease, and affects 1-2% of individuals ages 65 years and older worldwide (Mhyre et al., 2012; Kowal et al., 2013). At present, there are no blood or laboratory tests to diagnose non-genetic cases of PD. Diagnosis is primarily based on a patient's medical history and neurological examination. An additional hallmark that supports a PD diagnosis is a patient's improvement after starting medication. While current treatments provide symptomatic relief, there is still no therapy available to halt or slow the progression of the disease. Although a cure for PD remains elusive, existing treatments-such as medications, surgical interventions, and therapies like physiotherapy and occupational therapy-help manage key symptoms and preserve quality of life for as long as possible (National Health Service, 2022; National Institute on Aging, 2022).

In 2023, there were 2,636,930 diagnosed prevalent cases of PD among men and women ages 18 years and older across the 7MM. The US had the highest number of cases at 974,348, while Spain had the fewest, with 131,264 cases. Across the 7MM, the diagnosed prevalent cases of PD are projected to rise to 3,147,624 cases by 2033 at an annual growth rate (AGR) of 1.94% over the forecast period. This increase in the diagnosed prevalent cases of PD across the 7MM is primarily attributed to changes in the underlying population demographics, as GlobalData epidemiologists assumed a constant prevalence rate during the forecast period.

Scope

• This report provides an overview of the risk factors, comorbidities, and global and historical trends for PD in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).
• The report features a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex and age (beginning at age 18 years and ending at ages 85 years and older).
• The diagnosed prevalent cases are further categorized by Hoehn and Yahr (HY) clinical staging (stages I, II, III, IV, and V) and grouped into early (equivalent to HY clinical stages I-II), moderate-advanced (equivalent to HY clinical stages III-V), and advanced (equivalent to HY clinical stages IV-V). Additionally, the report covers diagnosed prevalent cases based on the inheritance type, including sporadic (idiopathic) and familial forms of PD.
• It also includes segments on motor complications, such as motor fluctuations and levodopa-induced dyskinesia, as well as neuropsychiatric complications, classified into psychosis, dementia, and hallucinations.
• To forecast the diagnosed prevalent cases of PD in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data. In addition, the forecast is supported by robust, country-specific data obtained from various authentic sources, such as research articles published in peer-reviewed journals.

Reasons to Buy

• The Parkinson's disease (PD) epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global PD market.
• Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for PD therapeutics in each of the markets covered.

Table of Contents

Table of Contents

• About GlobalData

1 Parkinson's Disease: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
  • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
  • 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
  • 2.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
  • 2.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
• 2.5 Epidemiological forecast for PD (2023-33)
  • 2.5.1 Diagnosed prevalent cases of PD
  • 2.5.2 Age-specific diagnosed prevalent cases of PD
  • 2.5.3 Sex-specific diagnosed prevalent cases of PD
  • 2.5.4 Diagnosed prevalent cases of PD by HY clinical staging
  • 2.5.5 Diagnosed prevalent cases of PD by type
  • 2.5.6 Diagnosed prevalent cases of PD by inheritance type
  • 2.5.7 Diagnosed prevalent cases of PD by motor complications
  • 2.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us